News &

Press

venBio news

“venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies.”

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Ventyx Biosciences announces pipeline updates and highlights strategic priorities at investor R&D day

Jan 23, 2023

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

Jan 5, 2023

Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply

Aug 12, 2021

Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply

Aug 12, 2021

Elevation Oncology Announces Pricing of Initial Public Offering

Jun 24, 2021

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Jun 15, 2021

Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.

Jun 8, 2021

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2024 venBio. All Rights Reserved.